Romiplostim impact post-auto HCT for multiple myeloma or lymphoma

Scordo M, Gilbert LJ, Hanley DM, et al. Open-Label, Pilot Study of Romiplostim for Thrombocytopenia After Autologous Hematopoietic Cell Transplantation. Blood Advances. 2022; (doi: 10.1182/bloodadvances.2022007838).

An open-label, pilot study found that the thrombopoietin receptor agonist romiplostim enhanced platelet recovery following autologous hematopoietic cell transplantation (autoHCT), without reducing the duration and depth of platelet nadir. A total of 59 multiple myeloma or lymphoma patients received weekly romiplostim from +1 day after autoHCT until the platelet count was >50 x 109/L without transfusion. The median number of days of grade 4 thrombocytopenia or days requiring transfusions, time to platelet engraftment, and number of platelets transfusions during transplantation for the romiplostim-treated patients and retrospective data for 853 romiplostim-naive patients were similar. Enhanced platelet recovery to normal values for the romiplostim recipients began at around +15 days. Compared with no romiplostim, matched cohort multivariable analyses linked romiplostim treatment with a higher platelet count by an average of 40 x 109/L at day +21 and 118 x 109/L at day +30. A low-risk pulmonary embolism in a patient with multiple myeloma was the only adverse event possibly attributed to romiplostim.

Read More

Tags: patient care, transplantation, Cellular therapy, Lymphoma, Haploidentical Transplants, response, hematopoietic, Research, donor, T cells, T cell, hematopoietic cell transplantation, haploidentical-HCT